Entering text into the input field will update the search result below

Sarepta gets modest bump from Edelman's bullish comments on CNBC; shares up 1%

  • Sarepta Therapeutics (SRPT +0.8%) bucks biotech's down day on average volume. On CNBC, hedge fund manage Joe Edelman re-emphasized his confidence that DMD candidate eteplirsen will be approved by the FDA.
  • The Ad Comm review is scheduled for April 25 followed by the PDUFA date on May 26.
  • This is a superb example of the prominence (risk) of a binary event for biotech investors. It will be either feast or famine. BioMarin Pharmaceutical (BMRN -0.4%) longs felt the sting of rejection a few months ago with its DMD candidate drisapersen.
  • Previously: FDA rejects BioMarin's drisapersen for Duchenne muscular dystrophy (Jan. 14)
  • Previously: Ad Comm fails to back BioMarin's drisapersen for DMD (Nov. 24, 2015)

Recommended For You

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT--
Sarepta Therapeutics, Inc.